How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations
- PMID: 19491045
- DOI: 10.1016/j.nbt.2009.03.012
How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations
Abstract
Antibody formation as an immune reaction to a 'foreign' protein antigen is an expected physiological reaction that is in many cases intentionally triggered, for example in the case of vaccinations. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to assess an unwanted immune response following the administration of a biological drug. In this article, we provide an in-depth regulatory discussion on key principles of systematic evaluation of immunogenicity during development of biotechnological medicinal products, including examples.
Similar articles
-
Immunogenicity and its impact on benefit/risk considerations in the authorisation of biopharmaceuticals.Curr Drug Saf. 2010 Oct;5(4):287-92. doi: 10.2174/157488610792245993. Curr Drug Saf. 2010. PMID: 20615175
-
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.J Immunol Methods. 2004 Jun;289(1-2):1-16. doi: 10.1016/j.jim.2004.06.002. J Immunol Methods. 2004. PMID: 15251407
-
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81. doi: 10.1016/j.jpba.2008.09.020. Epub 2008 Sep 19. J Pharm Biomed Anal. 2008. PMID: 18993008 Review.
-
[The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):731-9. doi: 10.1007/s00103-008-0579-5. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008. PMID: 18584106 German.
-
Biosimilars and regulatory authorities.Nephron Clin Pract. 2011;117(1):c1-7. doi: 10.1159/000319640. Epub 2010 Aug 3. Nephron Clin Pract. 2011. PMID: 20689318 Review.
Cited by
-
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24. AAPS J. 2014. PMID: 24764037 Free PMC article.
-
From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.Clin Exp Immunol. 2016 May;184(2):137-46. doi: 10.1111/cei.12742. Epub 2016 Jan 19. Clin Exp Immunol. 2016. PMID: 26597698 Free PMC article. Review.
-
Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.J Pharm Sci. 2015 May;104(5):1575-91. doi: 10.1002/jps.24379. Epub 2015 Mar 5. J Pharm Sci. 2015. PMID: 25753756 Free PMC article.
-
Protein particulate detection issues in biotherapeutics development--current status.AAPS PharmSciTech. 2012 Jun;13(2):732-46. doi: 10.1208/s12249-012-9793-4. Epub 2012 May 8. AAPS PharmSciTech. 2012. PMID: 22566174 Free PMC article. Review.
-
European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.MAbs. 2009 Sep-Oct;1(5):394-416. doi: 10.4161/mabs.1.5.9630. Epub 2009 Sep 25. MAbs. 2009. PMID: 20065643 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
